Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis.
Adverse events
Hepatocellular carcinoma
Learning curve
Prognosis
Sorafenib
Journal
Liver cancer
ISSN: 2235-1795
Titre abrégé: Liver Cancer
Pays: Switzerland
ID NLM: 101597993
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
08
08
2018
accepted:
20
01
2019
entrez:
5
12
2019
pubmed:
5
12
2019
medline:
5
12
2019
Statut:
ppublish
Résumé
Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study aimed to assess, in real life, if this translates into a better prognosis. This was a retrospective study of advanced HCC patients treated with sorafenib between 2007 and 2017. 188 advanced HCC patients received > 4 weeks of sorafenib. Median treatment duration was 5.4 months and median overall survival (mOS) 10 months (95% confidence interval 15-27). Sorafenib was initiated in 65 patients in 2007-2012 and 123 in 2013-2017. Both groups were comparable except for Barcelona Clinic liver cancer class. Tumor progression, disease control (DC) rate, and incidence of toxicity were similar in the 2 periods, but the duration of treatment (4.3 vs. 5.9 months; When comparing 2 periods of treatment in advanced HCC patients under sorafenib, duration of treatment and mOS were higher in the recent period. While mOS did not differ for patients who progressed, it was 2-fold higher in the recent period for those who had tumor control. Improvements in the use of sorafenib seem to be associated with better outcomes limited to patients with DC.
Sections du résumé
BACKGROUND
BACKGROUND
Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study aimed to assess, in real life, if this translates into a better prognosis.
METHODS
METHODS
This was a retrospective study of advanced HCC patients treated with sorafenib between 2007 and 2017.
RESULTS
RESULTS
188 advanced HCC patients received > 4 weeks of sorafenib. Median treatment duration was 5.4 months and median overall survival (mOS) 10 months (95% confidence interval 15-27). Sorafenib was initiated in 65 patients in 2007-2012 and 123 in 2013-2017. Both groups were comparable except for Barcelona Clinic liver cancer class. Tumor progression, disease control (DC) rate, and incidence of toxicity were similar in the 2 periods, but the duration of treatment (4.3 vs. 5.9 months;
CONCLUSION
CONCLUSIONS
When comparing 2 periods of treatment in advanced HCC patients under sorafenib, duration of treatment and mOS were higher in the recent period. While mOS did not differ for patients who progressed, it was 2-fold higher in the recent period for those who had tumor control. Improvements in the use of sorafenib seem to be associated with better outcomes limited to patients with DC.
Identifiants
pubmed: 31799203
doi: 10.1159/000497161
pii: lic-0008-0457
pmc: PMC6883434
doi:
Types de publication
Journal Article
Langues
eng
Pagination
457-467Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
JLR is a Board member of Bayer, BMS, BTG, Terumo, and Astra-Zeneca. XA is a Board member of Bayer. GP grant from Bayer; MB is a Board member of Merck-Schering Plough, Janssen, Roche, Gilead, Novartis, and Bayer.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Support Oncol. 2011 Jan-Feb;9(1):13-23
pubmed: 21465734
J Hepatol. 2016 Dec;65(6):1140-1147
pubmed: 27469901
Eur J Cancer. 2010 Sep;46(13):2432-40
pubmed: 20656473
Liver Cancer. 2017 Jun;6(3):216-226
pubmed: 29234628
Lancet Oncol. 2015 Oct;16(13):1344-54
pubmed: 26361969
J Clin Oncol. 2013 Oct 1;31(28):3517-24
pubmed: 23980084
J Hepatol. 2014 Aug;61(2):318-24
pubmed: 24703956
Liver Cancer. 2017 Nov;6(4):337-348
pubmed: 29234637
Cancer. 2012 Jan 1;118(1):147-56
pubmed: 21713764
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Semin Oncol. 2014 Feb;41 Suppl 2:S1-S16
pubmed: 24576654
Hepatology. 2018 Feb;67(2):612-622
pubmed: 28898447
J Clin Oncol. 2006 Sep 10;24(26):4293-300
pubmed: 16908937
Nat Rev Clin Oncol. 2014 Feb;11(2):91-9
pubmed: 24445516
Crit Rev Oncol Hematol. 2012 Jun;82(3):378-86
pubmed: 21944842
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Clin Oncol. 2015 Jan 10;33(2):172-9
pubmed: 25488963
J Clin Oncol. 2013 Nov 10;31(32):4067-75
pubmed: 24081937
J Clin Oncol. 2015 Mar 10;33(8):894-900
pubmed: 25667293
Oncologist. 2014 Apr;19(4):394-402
pubmed: 24652387
J Clin Oncol. 2005 Feb 10;23(5):965-72
pubmed: 15613696